Since last year, a high-dose influenza vaccine has been available in Switzerland in addition to the standard vaccines, which is recommended and approved for people over 75 and for people aged 65 and over with an additional risk factor. Empirical data confirm the higher efficacy of quadrivalent high-dose compared to quadrivalent standard-dose influenza vaccines in these age groups.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Arterial hypertension: ESC guideline 2024 in focus
New category “elevated blood pressure” – what are the therapeutic implications?
- Low-grade pediatric gliomas
Consideration of the tumor microenvironment opens up new treatment options
- Palliative care symptom and needs assessment.
What screening tools are helpful?
- Patient-centered rounds in medicine
Aligning care with the patient
- HIV: antiretroviral therapy (ART)
Single-tablet regimens support adherence
- Rare pulmonary syndromes
Yellow nail and Swyer-James syndrome
- Vaccinations against viral respiratory infections
Influenza, Covid-19 and RSV – Update 2025
- GLP1-RA therapy